Metvix (Methyl Aminolevulinate)

Methyl Aminolevulinate is a prodrug that is taken up by skin cells and converted intracellularly into protoporphyrin IX. When the treated area is exposed to a defined wavelength of light, protoporphyrin IX generates reactive oxygen species that cause localized oxidative damage, leading to the selective removal of dysplastic keratinocytes.

The prescribed amount of Metvix is determined by the treating physician based on the size, number and location of the actinic keratosis lesions. The prescriber decides the exact quantity of cream to apply, the incubation time before illumination, and the light‑dose parameters for each patient.

Safety data for Metvix in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Metvix offers a photodynamic approach that selectively destroys abnormal cells while sparing surrounding healthy tissue, which differs from topical agents such as 5‑fluorouracil or imiquimod that act through cytotoxic or immune‑modulating mechanisms. Photodynamic therapy can be advantageous for field‑directed treatment of multiple lesions and may result in faster cosmetic recovery.

Metvix should be stored at room temperature, below 25 °C, in its original packaging. The container must be kept closed, protected from light, and stored away from moisture. Do not freeze the product, and discard any cream that appears discolored or contaminated.

Metvix is applied topically to the cleaned, dry lesion(s) by a healthcare professional. After a defined incubation period (usually a few hours), the treated area is illuminated with a specific wavelength of light for a set duration. The procedure is performed in a clinical setting under controlled lighting conditions.

The most serious risks include severe photosensitivity reactions that can extend beyond the treated area, secondary infection of the treated skin, persistent scarring or ulceration, and rare systemic hypersensitivity responses. Patients should be monitored closely for any signs of these complications and advised to avoid additional UV exposure.

Metvix is contraindicated in patients with known hypersensitivity to methyl aminolevulinate or any component of the cream, those with porphyria or other photosensitivity disorders, and individuals with extensive open wounds or active infections at the intended treatment site. Caution is also advised for patients taking systemic photosensitizing medications.